Silence Therapeutics (SLN)

• Market cap: $292M
• 1 day: -0.64%
• 5 days: 3.51%
• 1 month: 37.25%
• 3 months: -0.16%
• 6 months: 18.81%
• Year to date: 0.65%
• 1 year: 37.56%
• 5 years: -75.02%
• 10 years: -68.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Employees: 116